Watson 667 (Divalproex sodium delayed release 500 mg)

Pill imprint Watson 667 has been identified as Divalproex sodium delayed release 500 mg.

Divalproex sodium is used in the treatment of bipolar disorder; migraine prevention; mania; hyperekplexia; epilepsy (and more), and belongs to the drug class fatty acid derivative anticonvulsants. When treating epilepsy and manic episodes associated with bipolar disorder: There is positive evidence of human fetal risk during pregnancy. When treating migraine: Not for use in pregnancy. Divalproex sodium 500 mg is not subject to the Controlled Substances Act.

See also related documents.

Imprint Search

Images for Watson 667

Divalproex sodium delayed release
Imprint:
Watson 667
Strength:
500 mg
Color:
Red
Shape:
Elliptical / Oval
Availability:
Prescription only
Drug Class:
Fatty acid derivative anticonvulsants
Pregnancy Category:
D - Positive evidence of risk - When treating epilepsy and manic episodes associated with bipolar disorder
X - Not for use in pregnancy - When treating migraine
CSA Schedule:
N - Not a controlled drug
Manufacturer:
Watson Laboratories, Inc.
National Drug Code (NDC):
62037-0667
Inactive Ingredients:
candelilla wax
cellacefate
silicon dioxide colloidal
croscarmellose sodium
dextrates
FD&C Red No. 40
hydroxypropyl cellulose
hypromellose 2910 (15 mPa.s)
ferrosoferric oxide
lactose monohydrate
magnesium stearate
microcrystalline cellulose
propylene glycol
silicon dioxide
titanium dioxide
triacetin
aluminum oxide

View Details Print Page

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2014 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide
(web1)